专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005046564A3 DIAGNOSIS AND TREATMENT OF LIVER FIBROSIS 审中-公开
标题翻译：肝纤维化的诊断与治疗
公开(公告)号：WO2005046564A3
公开(公告)日：2005-12-15
申请号：PCT/IL2004001048
申请日：2004-11-16
申请人： QUARK BIOTECH INC , SANKYO CO , MOR ORNA , FEINSTEIN LENA , SHAPIRA HAGIT
发明人： MOR ORNA , FEINSTEIN LENA , SHAPIRA HAGIT
IPC分类号： A61K20060101 , A61K31/00 , A61K48/00 , C07H21/04 , C07K16/40 , C12N15/113 , C12Q1/68
CPC分类号： A61K31/00 , A61K2039/505 , C07K16/40 , C12N15/1137 , C12N2310/11 , C12N2310/14 , C12Y301/04004
摘要： The present invention provides methods of treatment of liver fibrosis by identification and isolation of polynucleotide sequences, the expression of which is altered in liver fibrosis. The present invention also relates to the use of these isolated polynucleotides and the polypeptides encoded thereby as probes for diagnosis, for screening of treatment modalities and as targets for modulation in liver fibrosis. In particular, the present invention provides methods, compounds and pharmaceutical compositions for the treatment of liver fibrosis. Novel pharmaceutical compositions comprising oligonucleotides or antibodies are also provided.
摘要翻译：本发明提供了通过鉴定和分离肝纤维化中表达改变的多核苷酸序列来治疗肝纤维化的方法。本发明还涉及这些分离的多核苷酸和由其编码的多肽作为探针用于诊断，筛选治疗模式和作为肝纤维化调节的靶标的用途。特别地，本发明提供了用于治疗肝纤维化的方法，化合物和药物组合物。还提供了包含寡核苷酸或抗体的新型药物组合物。

2. 发明申请

WO2005072057A2 OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF FIBROTIC CONDITIONS AND OTHER DISEASES 审中-公开
标题翻译：用于治疗纤维性疾病和其他疾病的低分子化合物及其使用方法
公开(公告)号：WO2005072057A2
公开(公告)日：2005-08-11
申请号：PCT/IL2005/000102
申请日：2005-01-27
申请人： QUARK BIOTECH, INC. , MOR, Orna , FEINSTEIN, Elena
发明人： MOR, Orna , FEINSTEIN, Elena
IPC分类号： A61K48/00 , C07H21/04 , C07K14/705 , C07K16/18 , C07K16/40 , C12N9/10 , C12N15/113 , C12Q1/68
CPC分类号： C07H21/04 , C07K16/40 , C07K2317/21 , C07K2317/76 , C12N9/1044 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/321 , C12N2310/322 , C12Y203/02013 , C12N2310/3527 , C12N2310/3521
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.
摘要翻译：本发明涉及在转录后水平下调人TGaseII基因表达的双链化合物，优选寡核糖核苷酸（siRNA）。本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有纤维化疾病如肺，肾和肝纤维化或眼睛，瘢痕形成的患者的方法，其包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。本发明还涉及通过使用TGaseII多肽的抗体来治疗纤维化和其它疾病。

3. 发明申请

WO2004112566A3 DIAGNOSIS AND TREATMENT OF NEPHROPATHY 审中-公开
公开(公告)号：WO2004112566A3
公开(公告)日：2004-12-29
申请号：PCT/IL2004/000566
申请日：2004-06-24
申请人： QUARK BIOTECH, INC. , MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
发明人： MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
IPC分类号： A61K45/00
摘要： This application is directed to a method for the treatment of nephropathy or kidney fibrosis or glomerulosclerosis or chronic renal insufficiency in a subject in need of such treatment comprising administering to said subject an amount of an inhibitor of HNOEL-iso polypeptide sufficient to effect a substantial inhibition of the HNOEL-iso polypeptide so as to thereby treat the subject. This application is also directed to a process of obtaining a compound which inhibits human HNOEL-iso polypeptide This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular nephropathy, and to diagnostic aspects related to HNOEL-iso polypeptide.

4. 发明申请

WO2004112565A2 DIAGNOSIS AND TREATMENT OF LIVER, PULMONARY AND CARDIAC FIBROSIS 审中-公开
标题翻译：诊断和治疗肝，肺和心脏纤维化
公开(公告)号：WO2004112565A2
公开(公告)日：2004-12-29
申请号：PCT/IL2004/000565
申请日：2004-06-24
申请人： QUARK BIOTECH, INC. , MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
发明人： MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
IPC分类号： A61B
CPC分类号： G01N33/576 , A61K2039/505 , C07K14/47 , C07K16/18 , G01N2500/04 , G01N2800/085
摘要： This application is directed to a method for the treatment of fibrosis, preferably liver fibrosis, pulmonary fibrosis and cardiac fibrosis, in a subject in need of such treatment comprising administering to said subject an amount of an inhibitor of HNOEL-iso polypeptide sufficient to effect a substantial inhibition of the HNOEL-iso polypeptide so as to thereby treat the subject. This application is also directed to a process of obtaining a compound which inhibits human HNOEL-iso polypeptide. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis, and to diagnostic aspects related to HNOEL-iso polypeptide.
摘要翻译：本申请涉及在需要这种治疗的受试者中治疗纤维化，优选肝纤维化，肺纤维化和心脏纤维化的方法，包括向所述受试者施用一定量的足以产生HNO- 显着抑制HNOEL-iso多肽，从而治疗受试者。本申请还涉及获得抑制人HNOEL-iso多肽的化合物的方法。本申请还涉及通过该方法鉴定的化合物在制备用于治疗疾病，特别是纤维化以及与HNOEL-iso多肽相关的诊断方面的药物中的用途。

5. 发明申请

WO2005072057A3 OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF FIBROTIC CONDITIONS AND OTHER DISEASES 审中-公开
标题翻译：用于治疗纤维性疾病和其他疾病的低分子化合物及其使用方法
公开(公告)号：WO2005072057A3
公开(公告)日：2007-07-19
申请号：PCT/IL2005000102
申请日：2005-01-27
申请人： QUARK BIOTECH INC , MOR ORNA , FEINSTEIN ELENA
发明人： MOR ORNA , FEINSTEIN ELENA
IPC分类号： C07H21/04 , A61K31/70 , A61K48/00 , C07K14/705 , C07K16/18 , C07K16/40 , C12N9/10 , C12N15/113 , C12Q1/68
CPC分类号： C07H21/04 , C07K16/40 , C07K2317/21 , C07K2317/76 , C12N9/1044 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/321 , C12N2310/322 , C12Y203/02013 , C12N2310/3527 , C12N2310/3521
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.
摘要翻译：本发明涉及在转录后水平下调人TGaseII基因表达的双链化合物，优选寡核糖核苷酸（siRNA）。本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有纤维化疾病如肺，肾和肝纤维化或眼睛，瘢痕形成的患者的方法，其包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。本发明还涉及通过使用TGaseII多肽的抗体来治疗纤维化和其它疾病。

6. 发明申请

WO2004112566A2 DIAGNOSIS AND TREATMENT OF NEPHROPATHY 审中-公开
标题翻译：诊断和治疗NEPHROPATHY
公开(公告)号：WO2004112566A2
公开(公告)日：2004-12-29
申请号：PCT/IL2004/000566
申请日：2004-06-24
申请人： QUARK BIOTECH, INC. , MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
发明人： MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
IPC分类号： A61B
CPC分类号： A61K49/0008 , A01K2217/05 , A01K2227/105 , C07K16/18 , C12N15/113 , C12N2310/14 , G01N33/6893 , G01N2800/347
摘要： This application is directed to a method for the treatment of nephropathy or kidney fibrosis or glomerulosclerosis or chronic renal insufficiency in a subject in need of such treatment comprising administering to said subject an amount of an inhibitor of HNOEL-iso polypeptide sufficient to effect a substantial inhibition of the HNOEL-iso polypeptide so as to thereby treat the subject. This application is also directed to a process of obtaining a compound which inhibits human HNOEL-iso polypeptide This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular nephropathy, and to diagnostic aspects related to HNOEL-iso polypeptide.
摘要翻译：本申请涉及用于治疗需要这种治疗的受试者的肾病或肾纤维化或肾小球硬化或慢性肾功能不全的方法，包括向所述受试者施用足以实现基本抑制的量的HNOEL-iso多肽抑制剂的HNOEL-iso多肽，从而治疗受试者。本申请还涉及获得抑制人HNOEL-iso多肽的化合物的方法。本申请还涉及通过该方法鉴定的化合物在制备用于治疗疾病，特别是肾病的药物中的用途，以及与HNOEL-iso多肽相关的诊断方面。

7. 发明申请

WO2004100759A2 USE OF ENDO180 RECEPTOR FOR DIAGNOSIS AND TREATMENT OF DISEASE 审中-公开
标题翻译： ENDO180受体用于诊断和治疗疾病的使用
公开(公告)号：WO2004100759A2
公开(公告)日：2004-11-25
申请号：PCT/IL2004/000423
申请日：2004-05-18
申请人： QUARK BIOTECH, INC. , MOR, Orna , FEINSTEIN, Elena , FAERMAN, Alexander
发明人： MOR, Orna , FEINSTEIN, Elena , FAERMAN, Alexander
IPC分类号： A61B
CPC分类号： G01N33/5032 , G01N33/6872 , G01N2333/4724 , G01N2333/78
摘要： This application is directed to a process of identifying a compound capable of modulating activity of a human ENDO180 receptor that comprises the steps of measuring the binding of the ENDO180 receptor to an interactor with which the ENDO180 receptor interacts specifically in vivo, in the absence or presence of a compound, and determining whether the binding of the ENDO180 receptor to the interactor is affected by the compound. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis. This application also relates to the use of ENDO 180 modulators in treatment of disease.
摘要翻译：本申请涉及鉴定能够调节人ENDO180受体活性的化合物的方法，该方法包括以下步骤：在不存在或存在下测量ENDO180受体与ENDO180受体在体内特异性相互作用的相互作用因子的结合的化合物，并确定ENDO180受体与相互作用体的结合是否受化合物的影响。本申请还涉及通过该方法鉴定的化合物在制备用于治疗疾病，特别是纤维化的药物中的用途。本申请还涉及使用ENDO 180调节剂治疗疾病。

8. 发明申请

WO0122864A2 SEQUENCES CHARACTERISTIC OF BLADDER CANCER 审中-公开
标题翻译：膀胱癌的序列特征
公开(公告)号：WO0122864A2
公开(公告)日：2001-04-05
申请号：PCT/US0041005
申请日：2000-09-27
申请人： QUARK BIOTECH INC , KOHN KENNETH I , FEINSTEIN ELENA , MOR ORNA
发明人： FEINSTEIN ELENA , MOR ORNA
IPC分类号： C12P21/08 , C12Q1/68 , A61B
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： There is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a tissue sample from the patient for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathologies by administering to a patient a therapeutically effective amount of a ribozyme, antisense olignucleotide, or agonist against the nucleic acids sequences of the present invention are alos provided.
摘要翻译：提供了通过分析来自患者的组织样品中至少一种表达基因的存在来诊断患者中膀胱癌的存在的方法，其中表达基因的存在指示膀胱癌。本发明还提供了其表达指示膀胱癌的多核苷酸序列。还提供了膀胱癌的标记。还提供了通过筛选至少一种表达基因的存在来诊断膀胱癌的方法，其中表达基因的存在指示膀胱癌。提供了通过向患者施用治疗有效量的核酶，反义寡核苷酸或针对本发明的核酸序列的激动剂来治疗和调节膀胱癌相关病理的方法。

9. 发明申请

WO2004100759A3 ENDO 180 RECEPTOR FOR DIAGNOSIS AND TREATMENT 审中-公开
标题翻译：第180号接受诊断和治疗的受试者
公开(公告)号：WO2004100759A3
公开(公告)日：2009-03-12
申请号：PCT/IL2004000423
申请日：2004-05-18
申请人： QUARK BIOTECH INC , MOR ORNA , FEINSTEIN ELENA , FAERMAN ALEXANDER
发明人： MOR ORNA , FEINSTEIN ELENA , FAERMAN ALEXANDER
IPC分类号： G01N33/53 , A61B20060101 , C07H21/04 , C12P21/06 , G01N33/50 , G01N33/68
CPC分类号： G01N33/5032 , G01N33/6872 , G01N2333/4724 , G01N2333/78
摘要： This application is directed to a process of identifying a compound capable of modulating activity of a human ENDO180 receptor that comprises the steps of measuring the binding of the ENDO180 receptor to an interactor with which the ENDO180 receptor interacts specifically in vivo, in the absence or presence of a compound, and determining whether the binding of the ENDO180 receptor to the interactor is affected by the compound. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis. This application also relates to the use of ENDO 180 modulators in treatment of disease.
摘要翻译：本申请涉及鉴定能够调节人ENDO180受体活性的化合物的方法，该方法包括以下步骤：在不存在或存在下测量ENDO180受体与ENDO180受体在体内特异性相互作用的相互作用因子的结合的化合物，并确定ENDO180受体与相互作用体的结合是否受化合物的影响。本申请还涉及通过该方法鉴定的化合物在制备用于治疗疾病，特别是纤维化的药物中的用途。本申请还涉及使用ENDO 180调节剂治疗疾病。

10. 发明申请

WO2006131925A3 OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF FIBROTIC CONDITIONS AND OTHER DISEASES 审中-公开
标题翻译：用于治疗纤维性疾病和其他疾病的低分子化合物及其使用方法
公开(公告)号：WO2006131925A3
公开(公告)日：2007-08-02
申请号：PCT/IL2006000671
申请日：2006-06-08
申请人： QUARK BIOTECH INC , MOR ORNA , FEINSTEIN ELENA
发明人： MOR ORNA , FEINSTEIN ELENA
IPC分类号： C07H21/04 , A01N43/04 , A61K31/70 , A61K49/04 , C12P21/06 , C12Q1/68
CPC分类号： C12N15/1137 , C12N2310/14 , C12Y203/02013
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a gene of the TGase family at post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from fibrotic disease such as kidney and liver fibrosis and ocular scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective amount so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGase polypeptides.
摘要翻译：本发明涉及在转录后水平下调TGase家族基因表达的双链化合物，优选寡核糖核苷酸。本发明还涉及包含该化合物或能够表达寡核糖核苷酸的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有纤维化疾病如肾脏和肝纤维化和眼瘢痕的患者的方法，其包括以治疗有效量向患者施用药物组合物，从而治疗患者。本发明还涉及通过使用对TGase多肽的抗体来治疗纤维化和其它疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式